advertising
-
1
Adams RD, Victor M, Ropper AH: “Enfermedades de los Nervios Periféricos,” in Principios de Neurología, ed by RD Adams, M Victor, AH Ropper, p 1159, Interamericana-McGraw-Hill, Mexico City, 1999..
-
2
Skre H: Genetics and clinical aspects of Charcot-Marie-Tooth’s disease. .Clin Genet 6::98. ,1974. .
-
3
Combarros-Pascual O: Enfermedad de Charcot-Marie-Tooth tipo 2. .Rev Neurol 30::79. ,2000. .
-
4
Warner LE, García CA, Lupski JR: Hereditary peripheral neuropathies: clinical forms, genetics and molecular mechanisms. .Annu Rev Med 50::263. ,1999. .
-
5
García CA: “The Clinical Features of Charcot-Marie-Tooth Disorders,” in Charcot-Marie-Tooth Disorders: A Handbook for Primary Care Physicians, ed by GJ Parry, p 5, Charcot-Marie-Tooth Association, Upland, PA, 1995..
-
6
Vance JM, Nicholson GA, Yamaoka LH, et al: Linkage of Charcot-Marie-Tooth neuropathy type 1A to chromosome 17. .Exp Neurol 104::186. ,1989. .
-
7
Timmerman V, Raeymaekers P, De Jonghe P, et al: Assignment of the Charcot-Marie-Tooth neuropathy type 1 (CMT 1A) gene to 17p11.2-p12. .Am J Hum Genet 47::680. ,1990. .
-
8
Matsunami N, Smith B, Ballard L, et al: Peripheral myelin protein-22 gene maps in the duplication in chromosome 17p11.2 associated with Charcot-Marie-Tooth 1A. .Nat Genet 1::176. ,1992. .
-
9
Roa BB, García CA, Suter U, et al: Charcot-Marie-Tooth disease type 1A: association with a spontaneous point mutation in the PMP-22 gene. .N Engl J Med 329::96. ,1993. .
-
10
Bird TD, Ott J, Giblett TR: Evidence for linkage of Charcot-Marie-Tooth neuropathy to the Duffy locus on chromosome 1. .Am J Hum Genet 34::388. ,1982. .
-
11
Guiloff PJ, Thomas PK, Contreras M, et al: Linkage of autosomal dominant type I hereditary motor and sensory neuropathy to the Duffy locus on chromosome 1. .J Neurol Neurosurg Psychiatry 45::669. ,1982. .
-
12
Hayasaka K, Himoro M, Sato W, et al: Charcot-Marie-Tooth neuropathy type 1B is associated with mutations of the myelin P0 gene. .Nat Genet 5::31. ,1993. .
-
13
Kulkens T, Bolhius PA, Wolterman RA, et al: Deletion of the serine 34 codon from the major peripheral myelin protein P0 gene in Charcot-Marie-Tooth disease type 1B. .Nat Genet 5::35. ,1993. .
-
14
Warner LE, Mancias P, Butler IJ, et al: Mutations in the early growth response 2 (EGR-2) gene are associated with hereditary myelinopathies. .Nat Genet 18::382. ,1998. .
-
15
Holmes JR, Hansen ST: Foot and ankle manifestations of Charcot-Marie-Tooth disease. .Foot Ankle 14::476. ,1993. .
-
16
Sabir M, Lyttle D: Pathogenesis of pes cavus in Charcot-Marie-Tooth disease. .Clin Orthop 175::173. ,1983. .
-
17
Mann RA, Missirian J: Pathophysiology of Charcot-Marie-Tooth disease. .Clin Orthop 234::221. ,1988. .
-
18
Alexander IJ, Johnson KA: Assessment and management of pes cavus in Charcot-Marie-Tooth disease. .Clin Orthop 246::273. ,1989. .
-
19
American Society of Health-System Pharmacists: “Antineoplastic Agents,” in American Hospital Formulary Service Drug Information 1999, p 1021, American Society of Health-System Pharmacists, Bethesda, MD, 1999..
-
20
Hilkens PHE, Van den Bent MJ: Chemotherapy-induced peripheral neuropathy. .J Peripher Nerv Syst 2::350. ,1997. .
-
21
Graf WD, Chance PF, Lensch MW, et al: Severe vincristine neuropathy in Charcot-Marie-Tooth disease type 1A. .Cancer 77::1356. ,1996. .
-
22
Weiden PL, Wright SE: Vincristine neurotoxicity. .N Engl J Med 286::1369. ,1972. .
-
23
Hildebrand J, Kenis Y, Mubashir BA, et al: Vincristine neurotoxicity. .N Engl J Med 287::517. ,1972. .
-
24
Uno S, Katayama K, Dobashi N, et al: Acute vincristine neurotoxicity in a non-Hodgkin’s lymphoma patient with Charcot-Marie-Tooth disease [abstract]. .Rinsho Ketsueki 40::414. ,1999. .
-
25
Olek MJ, Bordeaux B, Leshner RT: Charcot-Marie-Tooth disease type I diagnosed in a 5 year old boy after vincristine neurotoxicity, resulting in maternal diagnosis. .J Am Osteopath Assoc 99::165. ,1999. .
-
26
Neuman Y, Toren A, Rechavi G, et al: Vincristine treatment triggering the expression of asymptomatic Charcot-Marie-Tooth disease. .Med Pediatr Oncol 26::280. ,1996. .
-
27
Igarashi M, Thompson EI, Rivera GK: Vincristine neuropathy in type I and type II Charcot-Marie-Tooth disease (hereditary motor sensory neuropathy). .Med Pediatr Oncol 25::113. ,1995. .
-
28
Griffiths JD, Stark RJ, Ding JC, et al: Vincristine neurotoxicity in Charcot-Marie-Tooth syndrome. .Med J Aust 143::305. ,1985. .
-
29
Hogan-Dann CM, Fellmeth WG, McGuire SA, et al: Polyneuropathy following vincristine therapy in two patients with Charcot-Marie-Tooth syndrome. .JAMA 252::2862. ,1984. .
-
30
Mercuri E, Poultron J, Buck J, et al: Vincristine treatment revealing asymptomatic hereditary motor sensory neuropathy type 1A. .Arch Dis Child 81::442. ,1999. .
-
31
McGuire SA, Ghospe SM, Dahl G: Acute vincristine neurotoxicity in the presence of hereditary motor and sensory neuropathy type I. .Med Pediatr Oncol 17::520. ,1989. .
-
32
Naumann R, Mohm J, Reuner U, et al: Early recognition of hereditary motor and sensory neuropathy type 1 can avoid life-threatening vincristine neurotoxicity. .Br J Haematol 115::323. ,2001. .
-
33
Mougdil SS, Riggs JE: Fulminant peripheral neuropathy with severe quadriparesis associated with vincristine therapy. .Ann Pharmacother 34::1136. ,2000. .
-
34
Hildebrandt G, Holler E, Woenkhaus M, et al: Acute deterioration of Charcot-Marie-Tooth disease 1A (CMT 1A) following 2 mg of vincristine chemotherapy. .Ann Oncol 11::743. ,2000. .
-
35
Tanner KD, Levine JD, Topp KS: Microtubule disorientation and axonal swelling in unmyelinated sensory axons during vincristine-induced painful neuropathy in rats. .J Comp Neurol 395::481. ,1998. .
-
36
Topp KS, Tanner KD, Levine JD: Damage to the cytoskeleton of large diameter sensory neurons and myelinated axons in vincristine-induced painful peripheral neuropathy in the rat. .J Comp Neurol 424::563. ,2000. .
-
37
Green LS, Donoso JA, Heller-Bettinger IE, et al: Axonal transport disturbances in vincristine-induced peripheral neuropathy. .Ann Neurol 1::255. ,1977. .
-
38
Wang MS, Wu Y, Culver DG, et al: Pathogenesis of axonal degeneration: parallels between Wallerian degeneration and vincristine neuropathy. .J Neuropathol Exp Neurol 59::599. ,2000. .
-
39
Bartus R: The calpain hypothesis in neurodegeneration: evidence for a common cytotoxic pathway. .Neuroscientist 3::314. ,1997. .
-
40
Rosenthal S, Kaufman S: Vincristine neurotoxicity. .Ann Intern Med 80::733. ,1974. .
-
41
Geni C, Gaio JM, Mallaret M, et al: Maladie de Charcot-Marie-Tooth révélée par un traitment á la vincristine au cours d’une maladie de Hodking familiale. .Ann Med Interne (Paris) 141::709. ,1990. .
-
42
Oshen L: “Review of Adult Foot Radiology,” in Hallux Valgus and Forefoot Surgery, ed by VJ Hetherington, p 67, Churchill Livingstone, New York, 1994..
Charcot-Marie-Tooth Disease and Vincristine
Search for other papers by Ángel M. Orejana-García in
Current site
Google Scholar
PubMed
Search for other papers by Javier Pascual-Huerta in
Current site
Google Scholar
PubMed
Search for other papers by Andrés Pérez-Melero in
Current site
Google Scholar
PubMed
This article reports on a case of sensorimotor neuropathy in a 55-year-old man that developed after vincristine therapy. Subsequent biopsy of the sural nerve and electromyographic studies revealed the presence of Charcot-Marie-Tooth disease. Only 17 patients who developed severe neuropathy with very low accumulated doses of vincristine have been described in the literature. Pain and lateral ankle instability were treated with a functional orthosis. Orthopedic treatment and the biomechanical basis of foot and ankle problems in patients with vincristine therapy–induced Charcot-Marie-Tooth disease are discussed. (J Am Podiatr Med Assoc 93(3): 229-233, 2003)
advertising
